FDA GUIDANCE DOCUMENT: Sterile Drug Products Produced by Aseptic Processing —Current Good Manufacturing Practice

This final guidance outlines FDA’s expectations for aseptic manufacturing of sterile drug products, providing recommendations on facility design, environmental controls, personnel practices, equipment qualification, and process validation. Aseptic processing involves sterilizing each component (drug, container, closure, excipients as applicable) prior to assembly. The guidance emphasizes that sterility assurance is achieved through a coordinated system of controls, not a single step.

Scope

• Applies to cGMP manufacture of sterile drugs and biologics for both commercial and clinical production.

• Relevant to any product where sterility is achieved through aseptic processing rather than terminal sterilization.

Core Principle

• Sterility assurance depends on exclusion of microorganisms throughout the process.

• Personnel are the primary contamination risk; minimizing their direct interaction with the critical zone is essential. And interventions must be strictly limited and simulated during aseptic process validation.

• Advanced barrier technologies (isolators, RABS) are encouraged.

Key Pillars

1. Facility & Environmental Control

   • Critical areas: ISO 5; background: ISO 7 or ISO 8 depending on activity.

   • HEPA-filtered air supply; positive pressure cascade from cleanest to less clean areas.

   • Barrier systems to separate operators from exposed product.

2. Personnel

   • Initial and ongoing training in aseptic technique and microbiology.

   • Qualification includes gowning tests and aseptic process simulations.

   • Use of sterile, non-shedding garments.

3. Sterilization & Depyrogenation

   • Validated sterilization methods (e.g., moist heat, dry heat, filtration).

   • Dry heat depyrogenation for glassware and vials.

   • Filter validation using bacterial challenge tests.

4. Process Validation (Media Fills)

   • Simulate worst-case conditions with a sterile nutrient medium.

   • Incubate 14 days; no contaminated units acceptable in small fills, and very low contamination rates (per FDA tables) tolerated in large fills. Any positive requires investigation.

   • Any contamination triggers investigation.

5. Environmental Monitoring

   • Continuous non-viable particle monitoring with routine trend analysis and action/alert levels tied to ISO classification.

   • Routine viable monitoring (air, surfaces, personnel).

   • Action levels defined by cleanroom classification.